Skip to main content
SpringerLink
Log in

Clinically Important Drug Interactions with Anticoagulants

An Update

  • Review Article
  • Drug Interactions
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Coumarin derivatives combine 3 unfavourable properties which make them prone to potentially life threatening drug-drug interactions: (i) high protein binding; (ii) cytochrome P450 dependent metabolism; and (iii) a narrow therapeutic range.

An entire list of drugs which are supposed to interact with coumarins (mostly with warfarin) comprises about 250 different compounds. Noteworthy are the interactions with cardiovascular or antilipidaemic drugs which are often coadministered with coumarins: amiodarone, propafenone and fibrates. Cardiovascular drugs which are obviously devoid or proven to be devoid of an interaction are angiotensin converting enzyme (ACE) inhibitors, calcium antagonists, β-blockers and cardiac glycosides. There are several other drugs which enhance the hypopro-thrombinaemic response to coumarins by various mechanisms: inhibitors of the elimination of the eutomer S-(−)-warfarin (e.g. miconazole, phenylbutazone), combined with protein binding displacement (e.g. sulfinpyrazone, phenylbutazone), synergistic hypoprothrombinaemia (e.g. cefazoline). Furthermore, bleeding complications may occur with drugs affecting platelet function [aspirin (acetylsali-cylic acid) and several nonsteroidal anti-inflammatories (NSAIDs)]. Strong inducers of coumarin metabolism are rifampicin (rifampin) and carbamazepine. Biphasic interactions may occur where a drug first enhances the hypoprothrombinaemic response to a coumarin but has a sustained inducing effect on coumarin metabolism (e.g. phenytoin or sulfinpyrazone).

The complex response of coumarins to concomitant drug therapy makes it difficult to predict the occurrence and degree of a deterioration of anticoagulant control in individual patients. For clinical practice, it seems advisable that one should monitor for changes in prothrombin time when adding or deleting any newly approved drug or any drug suspected (e.g. on the basis of this review) to cause an interaction to patients on coumarin therapy. The onset of the adverse prothrombin time response might be from between 1 to 2 days up to 3 weeks (in case of phenprocoumon) after starting a concomitant drug regimen. With amiodarone, an adverse prothrombin time response might occur up to 2 months after initiating therapy.

For heparins, only a drug interaction with aspirin or nitroglycerin seems clinically relevant due to the possibility of coadministration during acute cardiac events. Both drugs are shown to enhance the activated partial thromboplastin time response to heparin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Koch-Weser J. Hemorrhagic reactions and drug interactions in 500 warfarin-treated patients. Clin Pharmacol Ther 1973; 14(1): 139

    Google Scholar 

  2. Jankel CA, McMillan JA, Martin BC. Effect of drug interactions on outcomes of patients receiving warfarin or theophyl-line. Am J Hosp Pharm 1994 Mar 1; 51: 661–6

    PubMed  CAS  Google Scholar 

  3. Koch-Weser J. Drug interactions in cardiovascular therapy. Am Heart J 1975 Jul; 90(1): 93–116

    PubMed  CAS  Google Scholar 

  4. Freedman MD, Olatidoye AG. Clinical significant drug interactions with the oral anticoagulants. Drug Saf 1994; 10(5): 381–94

    PubMed  CAS  Google Scholar 

  5. Wells PS, Holbrook AM, Crowther NR, et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994 Nov 1; 121(9): 676–83

    PubMed  CAS  Google Scholar 

  6. Kuhlmann J. Drug interaction studies during drug development: which, when, how? Int J Clin Pharmacol Ther 1994; 32: 305–11

    PubMed  CAS  Google Scholar 

  7. Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet 1986; 11: 483–504

    PubMed  CAS  Google Scholar 

  8. Shetty HGM, Fennerty AG, Routledge PA. Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy. Clin Pharmacokinet 1989; 16: 238–53

    PubMed  CAS  Google Scholar 

  9. Chan E, McLachlan A, O’Reilly R, et al. Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther 1994 Sep; 56(3): 286–94

    PubMed  CAS  Google Scholar 

  10. Chan E, McLachlan AJ, Pegg M, et al. Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 1994; 37: 563–9

    PubMed  CAS  Google Scholar 

  11. Bentley DP, Backhouse G, Hutchings A, et al. Investigation of patients with abnormal response to warfarin. Br J Clin Pharmacol 1986; 22: 37–41

    PubMed  CAS  Google Scholar 

  12. Mungall DR, Ludden TM, Marshall J, et al. Population pharmacokinetics of racemic warfarin in adult patients. J Pharmacokinet Biopharm 1985; 13(3): 213–27

    PubMed  CAS  Google Scholar 

  13. Toon S, Heimark LD, Trager WF, et al. Metabolic fate of phenprocoumon in humans. J Pharm Sci 1985 Oct; 74(10): 1037–40

    PubMed  CAS  Google Scholar 

  14. Chriske HW, Gross R, Hilger HH, et al. Pharmakokinetische Untersuchungen zur Phenprocoumon (Marcumar)-Resistenz. Verh Dtsch Ges Inn Med 1973; 79: 1311–4

    PubMed  CAS  Google Scholar 

  15. Husted S, Andreasen F. Individual variation in the response to phenprocoumon. Eur J Clin Pharmacol 1977; 11: 351–8

    PubMed  CAS  Google Scholar 

  16. Trenk D, Althen H, Jähnchen E, et al. Factors responsible for interindividual differences in the dose requirement of phenprocoumon. Eur J Clin Pharmacol 1987; 33: 49–54

    PubMed  CAS  Google Scholar 

  17. Jähnchen E, Meinertz T, Gilfrich H-J, et al. The enantiomers of phenprocoumon: pharmacodynamic and pharmacokinetic studies. Clin Pharmacol Ther 1976; 20(3): 342–9

    PubMed  Google Scholar 

  18. Dieterle W, Faigle JW, Montigel C, et al. Biotransformation and pharmacokinetics of acenocoumarol (SintromR) in man. Eur J Clin Pharmacol 1977; 11: 367–75

    PubMed  CAS  Google Scholar 

  19. Thijssen HHW, Baars LG. Active metabolites of acenocoumarol: do they contribute to the therapeutic effect? Br J Clin Pharmacol 1983; 16: 491–6

    PubMed  CAS  Google Scholar 

  20. Godbillon J, Richard J, Gerardin A, et al. Pharmacokinetics of the enantiomers of acenocoumarol in man. Br J Clin Pharmacol 1981; 12: 621–9

    PubMed  CAS  Google Scholar 

  21. Popovic J, Mikov M, Jakovljevic V. Pharmacokinetic analysis of a new acenocoumarol tablet formulation during a bio-equivalence study. Eur J Drug Metab Pharmacokinet 1994; 19(2): 85–9

    PubMed  CAS  Google Scholar 

  22. Meinertz T, Kasper W, Kahl C, et al. Anticoagulant activity of the enantiomers of acenocoumarol. Br J Clin Pharmacol 1978; 5: 187–8

    PubMed  CAS  Google Scholar 

  23. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995 Jul 6; 333(1): 11–17

    PubMed  CAS  Google Scholar 

  24. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995 Jul 6; 333(1): 5–10

    Google Scholar 

  25. Fihn SD. Aiming for safe anticoagulation. N Engl J Med 1995 Jul 6; 333(1): 54–5

    PubMed  CAS  Google Scholar 

  26. Rolan PE. Plasma protein binding displacement interactions: why are they still regarded as clinically important? Br J Clin Pharmacol 1994; 37: 125–8

    PubMed  CAS  Google Scholar 

  27. Toon S, Hopkins KJ, Garstang FM, et al. The warfarin-cimetidine interaction: stereochemical considerations. Br J Clin Pharmacol 1986; 21: 245–6

    PubMed  CAS  Google Scholar 

  28. Bell WR, Anderson KC, Noe DA, et al. Reduction in the plasma clearance rate of warfarin induced by cimetidine. Arch Intern Med 1986 Dec; 146: 2325–8

    PubMed  CAS  Google Scholar 

  29. Scott AK, Park BK, Breckenridge AM. Interaction between warfarin and propranolol. Br J Clin Pharmacol 1984; 17: 559–64

    PubMed  CAS  Google Scholar 

  30. Bax NDS, Lennard MS, Tucker GT, et al. The effect of β-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin after a single dose. Br J Clin Pharmacol 1984; 17: 553–7

    PubMed  CAS  Google Scholar 

  31. Spahn H, Kirch W, Mutschler E, et al. Pharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol. Br J Clin Pharmacol 1984; 17 Suppl. 1: 97S–102S

    PubMed  Google Scholar 

  32. Harder S, Brei R, Caspary S, et al. Lack of a pharmacokinetic interaction between carvedilol and digitoxin or phenprocoumon. Eur J Clin Pharmacol 1993; 44: 583–6

    PubMed  CAS  Google Scholar 

  33. Vinazzer H. Effect of the beta-blocking agent Visken on the action of coumarin. Int J Clin Pharmacol Biopharm 1975; 12: 458–60

    PubMed  CAS  Google Scholar 

  34. Gazzaninga AB, Stewart DR. Possible quinidine induced hemorrhage in a patient on warfarin sodium. N Engl J Med 1969; 280: 711

    Google Scholar 

  35. Sylvén C, Anderson P. Evidence that disopyramide does not interact with warfarin [letter]. BMJ 1983 Apr 9; 286: 1181

    PubMed  Google Scholar 

  36. Trenk D, Möhrke W, Warm L, et al. Determination of the interaction of 3S-hydroxy-10,11-dihydroquinidine on the pharmacokinetics and pharmacodynamics of warfarin. Arzneimittelforschung 1993; 43(8): 836–41

    PubMed  CAS  Google Scholar 

  37. Martinowitz U, Rabinowici J, Goldfarb D, et al. Interaction between warfarin sodium and amiodarone. N Engl J Med 1981 Mar 12; 304(11): 671–2

    PubMed  CAS  Google Scholar 

  38. Kerin NZ, Blevins RD, Goldman L, et al. The incidence, magnitude, and time course of the amiodarone-warfarin interaction. Arch Intern Med 1988 Aug; 148: 1779–81

    PubMed  CAS  Google Scholar 

  39. Almog S, Shafran N, Halkin H, et al. Mechanism of warfarin potentiation by amiodarone: dose — and concentration — dependent inhibition of warfarin elimination. Eur J Clin Pharmacol 1985; 28: 257–61

    PubMed  CAS  Google Scholar 

  40. O’Reilly RA, Trager WF, Rettie AE, et al. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin Pharmacol Ther 1987 Sep; 42(3): 290–4

    PubMed  Google Scholar 

  41. Caraco Y, Chajek-Shaul T. The incidence and clinical significance of amiodarone and acenocoumarol interaction. Thromb Haemost 1989; 62(3): 906–8

    PubMed  CAS  Google Scholar 

  42. Fondevila C, Meschengieser S, Lazzari MA. Amiodarone potentiates acenocoumarin. Thromb Res 1989; 53(2): 203–8

    PubMed  CAS  Google Scholar 

  43. Richard C, Riou B, Berdeaux A, et al. Prospective study of the potentiation of acenocoumarol by amiodarone. Eur J Clin Pharmacol 1985; 28: 625–9

    PubMed  CAS  Google Scholar 

  44. Kates RE, Yee Y-G, irsten EB. Interaction between warfarin and propafenone in healthy volunteer subjects. Clin Pharmacol Ther 1987 Sep; 42(3): 305–11

    PubMed  CAS  Google Scholar 

  45. Körst HA, Brandes J-W, Littmann K-P. Cave: Propafenon potenziert Wirkung von oralen Antikoagulantien. Med Klin 1981; 76(12): 349–50

    PubMed  Google Scholar 

  46. Benedek IH, King S-YP, Powell RJ, et al. Effect of moricizine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Clin Pharmacol 1992; 32: 558–63

    CAS  Google Scholar 

  47. Van Hecken A, De epeleire I, Verbesselt R, et al. Effect of benazepril, a converting enzyme inhibitor, on plasma levels and activity of acenocoumarol and warfarin. Int J Clin Pharmacol Res 1988; 8(5); 315–19

    PubMed  Google Scholar 

  48. Van Hecken A, Verhesselt R, Depré M, et al. Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. Eur J Clin Pharmacol 1993; 45: 291–3

    PubMed  Google Scholar 

  49. Boeijinga JK, Breimer DD, Kraay CJ, et al. Absence of interaction between the ACE inhibitor cilazapril and coumarin derivatives in elderly patients on long term oral anticoagulants. Proceedings of the British Pharmacological Society Meeting; 1991Dec 17–19: London. Br J Clin Pharmacol 1992 May; 33(5): 553P

    Google Scholar 

  50. Boeijinga JK, Matroos AW, van Maarschalkerweerd MW, et al. No interaction shown between ramipril and coumarine derivatives. Curr Ther Res 1988 Dec; 44(6): 902–8

    Google Scholar 

  51. Verho M, Malerczyk V, Grötsch H, et al. Absence of interaction between ramipril, a new ACE-inhibitor, and phenprocoumon, an anticoagulant agent. Pharmatherapeutics 1989; 5(6): 392–9

    CAS  Google Scholar 

  52. O’Reilly RA. Spironolactone and warfarin interaction. Clin Pharmacol Ther 1980 Feb; 27(2): 198–201

    PubMed  Google Scholar 

  53. O’Reilly RA, Sahud MA, Aggeler PM. Impact of aspirin and chlorthalidone on the pharmacodynamics of oral anticoagulant drugs in man. Ann NY Acad Sci 1971; 179: 173–86

    PubMed  Google Scholar 

  54. Robinson DS, Sylwester D. Interaction of commonly prescribed drugs and warfarin. Ann Intern Med 1970 Jun; 72(6): 853–6

    PubMed  CAS  Google Scholar 

  55. Sellers EM, Koch-Weser J. Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids. Clin Pharmacol Ther 1970; 11(4): 524–9

    PubMed  CAS  Google Scholar 

  56. Petrick RJ, Kronacher N, Alcena V. Interaction between warfarin and ethacrynic acid. JAMA 1975 Feb 24; 231(8): 843–4

    PubMed  CAS  Google Scholar 

  57. Donaldson DR, Sreeharan N, Crow MJ, et al. Assessment of the interaction of warfarin with aspirin and dipyridamole [letter]. Thromb Haemost 1982; 47(1): 77

    PubMed  CAS  Google Scholar 

  58. Chesebro JH, Fuster V, Elveback LR, et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983 May 15; 51: 1537–41

    PubMed  CAS  Google Scholar 

  59. Fagan SC. Safety of combination aspirin and anticoagulation in acute ischemic stroke. Ann Pharmacother 1994; 28: 441–3

    PubMed  CAS  Google Scholar 

  60. O’Reilly RA. Phenylbutazon and sulfinpyrazone interaction with oral anticoagulant phenprocoumon. Arch Intern Med 1982 Sep; 142: 1634–7

    PubMed  Google Scholar 

  61. Miners JO, Foenander T, Wanwimolruk S, et al. Interaction of sulphinpyrazone with warfarin. Eur J Clin Pharmacol 1982; 22: 327–31

    PubMed  CAS  Google Scholar 

  62. Heimark LD, Toon S, Gibaldi M, et al. The effect of sulfinpyrazone on the disposition of pseudoracemic phenprocoumon in humans. Clin Pharmacol Ther 1987 Sep; 42(3): 312–19

    PubMed  CAS  Google Scholar 

  63. Stoysich AM, Lucas BD, Mohiuddin SM, et al. Further elucidation of pharmacokinetic interaction between diltiazem and warfarin. Int J Clin Pharmacol Ther 1996; 34: 56–60

    PubMed  CAS  Google Scholar 

  64. Jähnchen E, Meinertz T, Gilfrich H-J, et al. Enhanced elimination of warfarin during treatment with cholestyramine. Br J Clin Pharmacol 1978; 5: 437–40

    PubMed  Google Scholar 

  65. Robinson DS, Benjamin DM, McCormick JJ. Interaction of warfarin and nonsystemic gastrointestinal drugs. Clin Pharmacocol Ther 1971; 12: 491–5

    CAS  Google Scholar 

  66. Meinertz T, Gilfrich H-J, Groth U, et al. Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine. Clin Pharmacol Ther 1977; 21(6): 731–5

    PubMed  CAS  Google Scholar 

  67. Harvengt C, Desager JP. Effect of colestipol, a new bile acid sequestrant, on the absorption of phenprocoumon in man. Eur J Clin Pharmacol 1973; 6(1): 19–21

    PubMed  CAS  Google Scholar 

  68. Hunninghake DB, Pollack E. Effect of bile acid sequestering agents on the absorption of aspirine, tolbutamide and warfarin. Fed Proc 1977; 36: 996

    Google Scholar 

  69. Bjornsson TD, Meffin PJ, Blaschke TF. Interaction of clofibrate with warfarin. I. Effect of clofibrate on the disposition of the optical enantiomorphs of warfarin. J Pharmacokinet Biopharm 1977; 5(5): 495–505

    PubMed  CAS  Google Scholar 

  70. Bjornsson TD, Meffin PJ, Swezey SE, et al. Effects of clofibrate and warfarin alone and in combination on the disposition of vitamin K 1. J Pharmacol Exp Ther 1979; 210: 322–6

    PubMed  CAS  Google Scholar 

  71. Zimmermann SW, Moorthy AV, Dreher WH, et al. Prospective trial of warfarin and dipyridamole in patients with membranoproliferative glomerulonephritis. Am J Med 1983; 75: 920–7

    Google Scholar 

  72. Ahmad S. Gemfibrozil interaction with warfarin sodium (coumadin). Chest 1990 Oct; 98(4): 1041–2

    PubMed  CAS  Google Scholar 

  73. Verstreate M, Boogaerts MA. Haematological disorders. In: Speight TM, editor. Avery’s drug treatment. 3rd ed. Auckland: Adis Press, 1987: 958–1022

    Google Scholar 

  74. Gaw A, Wosornu D. Simvastatin during warfarin therapy in hyperlipoproteinaemia. Lancet 1992 Oct 17; 340: 979–80

    PubMed  CAS  Google Scholar 

  75. Keech A, Collins R, McMahon S, et al. Oxford Cholesterol Study Group: three year follow up of the Oxford Cholesterol Study. Eur Heart J 1994; 15: 255–68

    PubMed  CAS  Google Scholar 

  76. Ahmad S. Lovastatin. Warfarin interaction. Arch Intern Med 1990 Nov; 150(11): 2407

    PubMed  Google Scholar 

  77. Jassal SV. Warfarin potentiated by proguanil. BMJ 1991 Sep 28; 303: 789

    Google Scholar 

  78. Heine P, Kewitz H, Wiegboldt K-A. The influence of hypoglycaemic sulphonylureas on elimination and efficacy of phenprocoumon following a single oral dose in diabetic patients. Eur J Clin Pharmacol 1976; 10: 31–3

    Google Scholar 

  79. Ohnhaus EE, Berger W, Duckert F, et al. The influence of dimethylbiguanide on phenprocoumon elimination and its mode of action. Klin Wochenschr 1983; 61: 851–8

    PubMed  CAS  Google Scholar 

  80. Serlin MJ, Sibeon RG, Mossman S, et al. Cimetidine: interaction with oral anticoagulants in man. Lancet 1979 Aug 18; II(8138): 317–19

    Google Scholar 

  81. Baciewicz AM, Morgan PJ. Ranitidine-warfarin interaction. Ann Intern Med 1990 Jan 1; 112(1): 76–7

    PubMed  CAS  Google Scholar 

  82. Desmond PV, Mashford ML, Harman PJ, et al. Decreased oral warfarin after ranitidine and cimetidine. Clin Pharmacol Ther 1984 Mar; 35(3): 338–41

    PubMed  CAS  Google Scholar 

  83. O’Reilly RA. Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. Arch Intern Med 1984 May; 144: 989–91

    PubMed  Google Scholar 

  84. Toon S, Hopkins KJ, Garstang FM, et al. Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. Eur J Clin Pharmacol 1987; 32: 165–72

    PubMed  CAS  Google Scholar 

  85. Harenberg J, Zimmermann R, Staiger C, et al. Lack of effect of cimetidine on action of phenprocoumon. Eur J Clin Pharmacol 1982; 23: 365–7

    PubMed  CAS  Google Scholar 

  86. De Lepeleire I, Van Hecken A, Verbesselt R et al. Lack of interaction between famotidine and warfarin. Int J Clin Pharmacol Res 1990; 10: 167–71

    PubMed  Google Scholar 

  87. Unge P, Svedberg L-E, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol 1992; 34: 509–12

    PubMed  CAS  Google Scholar 

  88. Duursema L, Müller FO, Schall R, et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol 1995; 39: 700–3

    PubMed  CAS  Google Scholar 

  89. Mungall D, Talbert RL, Phillips C, et al. Sucralfate and warfarin [letter]. Ann Intern Med 1983; 98: 557

    PubMed  CAS  Google Scholar 

  90. Neuvonen PJ, Jaakkola A, Tötterman J, et al. Clinically significant sucralfate-warfarin interaction is not likely. Br J Clin Pharmacol 1985; 20: 178–80

    PubMed  CAS  Google Scholar 

  91. Ambre JJ, Fischer LJ. Effect of coadministration of aluminum and magnesium hydroxides on absorption of anticoagulants in man. Clin Pharmacol Ther 1973; 14(2): 231–7

    PubMed  CAS  Google Scholar 

  92. Aggeler PM, O’Reilly RA, Leong L, et al. Potentiation of anticoagulant effect of warfarine by phenylbutazone. N Engl J Med 1976; 276: 496–501

    Google Scholar 

  93. Savitsky JP. Fenbufen-warfarin interaction in healthy volunteers. Clin Pharmacol Ther 1980 Feb; 27(2): 284

    Google Scholar 

  94. Vesell ES, Passananti T, Johnson AO. Failure of indomethacin and warfarin to interact in normal human volunteers. J Clin Pharmacol 1975; 15: 486–95

    PubMed  CAS  Google Scholar 

  95. Chan TYK, Lui SF, Chung SY, et al. Adverse interaction between warfarin and indomethacin. Drug Saf 1994; 10(3): 267–9

    PubMed  CAS  Google Scholar 

  96. Michot F, Ajdacic K, Glaus L. A double-blind clinical trial to determine if an interaction exists between diclofenac sodium and the oral anticoagulant acenocoumarol (Nicoumalone). J Int Med Res 1975; 3: 153–7

    PubMed  CAS  Google Scholar 

  97. Toon S, Holt BL, Mullins FGP, et al. Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1990; 30: 743–750

    PubMed  CAS  Google Scholar 

  98. Loftin I, Vesell ES. Interaction between sulindac and warfarin: different results in normal subjects and in an unuasual patient with a potassium-losing renal tubular defect. J Clin Pharmacol 1979; 19: 733–42

    PubMed  CAS  Google Scholar 

  99. Ross JRY, Beeley L. Sulindac. Prothrombin time and anticoagulants [letter]. Lancet 1979; II (1075)

  100. Carter SA. Potential effect of sulindac on response of prothrombin-time to oral anticoagulants [letter]. Lancet 1979 Sep 29; II: 698–9

    Google Scholar 

  101. Penner JA, Abbrecht PH. Lack of interaction between ibuprofen and warfarin. Curr Ther Res 1975; 18: 862

    PubMed  CAS  Google Scholar 

  102. Jacono A, Caso P, Gualtieri S, et al. Clinical study of possible interactions between indoprofen and oral anticoagulants. Eur J Rheumatol Inflamm 1981; 4: 32–5

    PubMed  CAS  Google Scholar 

  103. Flessner MF, Knight H. Prolongation of prothrombin time and severe gastrointestinal bleeding associated with combined use of warfarin and ketoprofen [letter]. JAMA 1988 Jan 15; 259(3): 353

    PubMed  CAS  Google Scholar 

  104. Mieszczak C, Winther K. Lack of interaction of ketoprofen with warfarin. Eur J Clin Pharmacol 1993; 44: 205–6

    PubMed  CAS  Google Scholar 

  105. Jain A, McMahon FG, Slattery JT, et al. Effect of naproxen on the steady-state serum concentration and anticoagulant activity of warfarin. Clin Pharmacol Ther 1979 Jan; 25(1): 61–6

    PubMed  CAS  Google Scholar 

  106. Slattery JT, Levy G, Jain A, et al. Effect of naproxen on the kinetics of elimination and anticoagulant activity of a single dose of warfarin. Clin Pharmacol Ther 1979 Jan; 25(1): 51–60

    PubMed  CAS  Google Scholar 

  107. Marbet GA, Duckert F, Walter M, et al. Interaction study between phenprocoumon and flurbiprofen. Curr Med Res Opin 1977; 5(1): 26–31

    PubMed  CAS  Google Scholar 

  108. Stricker BHC, Delhez JL. Interactions between flurbiprofen and coumarins [letter]. BMJ 1982 Sep 18; 285: 812–13

    PubMed  CAS  Google Scholar 

  109. Dürr J, Pfeiffer MH, Penth B, et al. Untersuchung zur Frage einer Interaktion von Tiaprofensäure und Phenprocoumon. Arzneimittelforschung 1981; 31 II(12): 2163–7

    Google Scholar 

  110. Meurice J. Interaction of tiaprofenic acid and acenocoumarol. Rheumatology 1982; 7: 111–17

    Google Scholar 

  111. Rhodes RS, Rhodes PJ, Klein C et al. A warfarin-piroxicam drug interaction. Drug Intell Clin Pharm 1985; 91: 556–8

    Google Scholar 

  112. Dahl SL, Ward JR. Pharmacology, clinical efficacy, and adverse effects of piroxicam, a new nonsteroidal anti-inflammatory agent. Pharmacotherapy 1982 Mar–Apr; 2(2): 80–9

    PubMed  CAS  Google Scholar 

  113. Farnham DJ. Studies of isoxicam in combination with aspirin, warfarin sodium and cimetidine. Semin Arthritis Rheum 1982; 12 Suppl. 2: 179–83

    Google Scholar 

  114. Eichler HG, Jung M, Kyrle PA, et al. Absence of interaction between tenoxicam and warfarin. Eur J Clin Pharmacol 1992; 42(2): 227–9

    PubMed  CAS  Google Scholar 

  115. Perucca E. Drug interactions with nimesulide. Drugs 1993; 46 Suppl. 1: 79–82

    PubMed  CAS  Google Scholar 

  116. Harder S, Thürmann P, Hermann R, et al. Effects of flupirtine coadministration on phenprocoumon plasma concentrations and prothrombin time. Int J Clin Pharmacol Ther 1994; 32(11): 577–81

    PubMed  CAS  Google Scholar 

  117. Boeijinga JJ, Boerstra EE, Ris P, et al. Interaction between paracetamol and coumarin anticoagulants. Lancet 1982 Feb 27; I: 506

    Google Scholar 

  118. O’Reilly RA. Interaction of chronic daily warfarin therapy and rifampin. Ann Intern Med 1975 Oct; 83(4): 506–8

    PubMed  Google Scholar 

  119. Heimark LD, Gibaldi M, Trager WF, et al. The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther 1987 Oct; 42(4): 388–94

    PubMed  CAS  Google Scholar 

  120. Boekhout-Mussert RJ, Bieger R, van Brummelen P, et al. Inhibition by rifampicin of the anticoagulant effect of phenprocoumon. JAMA 1974 Sep 30; 229(14): 1903–4

    PubMed  CAS  Google Scholar 

  121. Rosenthal AR, Self TH, Baker ED, et al. Interaction of isoniazid and warfarin. JAMA 1977 Nov 14; 238(20): 2177

    PubMed  CAS  Google Scholar 

  122. Bianco TM, Bussey HI, Farnett LE, et al. Potential warfarin-ciprofloxacin interaction in patients receiving long-term anti-coagulation. Pharmacotherapy 1992; 12(6): 435–9

    PubMed  CAS  Google Scholar 

  123. Rindone JP, Kelley CL, Jones WN, et al. Hypoprothrombinemic effect of warfarin not influenced by ciprofloxacin. Clin Pharm 1991 Feb; 10: 136–8

    PubMed  CAS  Google Scholar 

  124. Rocci ML, Vlasses PH, Distlerath LM, et al. Norfloxacin does not alter warfarin’s disposition or anticoagulant effect. J Clin Pharmacol 1990; 30: 728–32

    PubMed  Google Scholar 

  125. Millar E, Coles S, Wyld P, et al. Temafloxacin does not potentiate the anticoagulant effect of warfarin in healthy subjects. Clin Pharmacokinet 1992; 22 Suppl. 1: 102–6

    PubMed  CAS  Google Scholar 

  126. Sörgel F, Kinzig M. Pharmacokinetics of gyrase inhibitors, part 2: renal and hepatic elimination pathways and drug interactions. Am J Med 1993 Mar 22; 94 Suppl. 3A: 56S–69S

    PubMed  Google Scholar 

  127. Verho M, Malerczyk V, Rosenkranz B, et al. Absence of interaction between ofloxacin and phenprocoumon. Curr Med Res Opin 1987; 10(7): 474–9

    PubMed  CAS  Google Scholar 

  128. Toon S, Hopkins KJ, Garstang FM, et al. Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects. Clin Pharmacol Ther 1987 Jul; 42(1): 33–41

    PubMed  Google Scholar 

  129. Jolson HM, Tanner LA, Green L, et al. Adverse reaction reporting of interaction between warfarin and fluoroquinolones. Arch Intern Med 1991 May; 151: 1003–4

    PubMed  CAS  Google Scholar 

  130. Linville T, Matanin D. Norfloxacin and warfarin [letter]. Ann Intern Med 1989 May 1; 110(5): 751–2

    PubMed  CAS  Google Scholar 

  131. Mott FE, Murphy S, Hunt V. Ciprofloxacin and warfarin [letter]. Ann Intern Med 1989 Sep 15; 111(6): 542–3

    PubMed  CAS  Google Scholar 

  132. Linville D, Emory C, Graves L. Ciprofloxacin and warfarin interaction. Am J Med 1991 Jun; 90: 765

    PubMed  Google Scholar 

  133. Baciewicz AM, Ashar BH, Locke TW. Interaction of ofloxacin and warfarin. Ann Intern Med 1993 Dec 15; 119(12): 1223

    PubMed  CAS  Google Scholar 

  134. Leor J, Levartowsky D, Sharon C. Interaction between nalidixic acid and warfarin [letter]. Ann Intern Med 1987; 107: 601

    PubMed  CAS  Google Scholar 

  135. Hoffbrand BI. Interaction of nalidixic acid and warfarin [letter]. BMJ 1974 Jun 22; 2: 666

    PubMed  CAS  Google Scholar 

  136. Bachmann K, Schwartz, JI, Forney R, et al. The effect of erythromycin on the disposition kinetics of warfarin. Pharmacology 1984; 28: 171–6

    PubMed  CAS  Google Scholar 

  137. Sato RI, Gray DR, Brown SE. Warfarin interaction with erythromycin. Arch Intern Med 1984 Dec; 144: 2413–4

    PubMed  CAS  Google Scholar 

  138. Hassell D, Utt JK. Suspected interaction: warfarin and erythromycin. South Med J 1985; 78: 1015–6

    PubMed  CAS  Google Scholar 

  139. Grau E, Fontcuberta J, Félez J. Erythromycin: oral anticoagulants interaction [letter]. Arch Intern Med 1986 Aug; 146: 1639

    PubMed  CAS  Google Scholar 

  140. Paulsen O, Nilsson L-G, aint-Salvi B, et al. No effect of roxithromycin on pharmacokinetic or pharmacodynamic properties of warfarin and its enantiomers. Pharmacol Toxicol 1988; 63: 215–20

    PubMed  CAS  Google Scholar 

  141. Davis RL, Berman W, Wernly JA, et al. Warfarin-nafcillin interaction. J Pediatr 1991 Feb; 118(2): 300–3

    PubMed  CAS  Google Scholar 

  142. Taylor AT, Pritchard DC, Goldstein AO, et al. Continuation of warfarin-nafcillin interaction during dicloxacillin therapy. J Fam Pract 1994 Aug; 39(2): 182–5

    PubMed  CAS  Google Scholar 

  143. Angaran DM, Dias VC, Arom KV, et al. The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient. Ann Surg 1987 Aug; 206(2): 155–61

    PubMed  CAS  Google Scholar 

  144. Parker SW, Baxter J, Beam TR. Cefoperazone-induced coagulopathy. Lancet 1984 May 5; I: 1016

    Google Scholar 

  145. Cristiano P. Hypoprothrombinemia associated with cefoperazone treatment. Drug Intell Clin Pharm 1984 Apr; 18: 314–16

    PubMed  CAS  Google Scholar 

  146. Soto J, Sacristan JA, Alsar MJ, et al. Probable acenocoumarol-amoxycillin interaction. Acta Haematol 1993; 90: 195–7

    PubMed  CAS  Google Scholar 

  147. Cullen SI, Catalano PM. Griseofulvin-warfarin antagonism. JAMA 1967 Feb 20; 199(8): 582–3

    PubMed  CAS  Google Scholar 

  148. Kazmier FJ. A significant interaction between metronidazole and warfarin. Mayo Clin Proc 1976 Dec; 51: 782–4

    PubMed  CAS  Google Scholar 

  149. O’Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 1976 Aug 12; 295(7): 354–7

    PubMed  Google Scholar 

  150. Colquhoun MC, Daly M, Stewart P, et al. Interaction between warfarin and miconazole oral gel. Lancet 1987 Mar 21; I: 695–6

    Google Scholar 

  151. O’Reilly RA, Goulart DA, Kunze KL, et al. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther 1992 Jun; 51(6): 656–67

    PubMed  Google Scholar 

  152. Gericke KR. Possible interaction between warfarin and fluconazole. Pharmacotherapy 1993 Sep–Oct; 13(5): 508–9

    PubMed  CAS  Google Scholar 

  153. Yeh J, Soo S-C, Summerton C, et al. Potentiation of action of warfarin by itraconazole [letter]. BMJ 1990 Sep 29; 301: 669

    PubMed  CAS  Google Scholar 

  154. Smith AG. Potentiation of oral anticoagulants by ketoconazole. BMJ 1984 Jan 21; 288: 188–9

    PubMed  CAS  Google Scholar 

  155. Christensen LK, Skovsted L. Inhibition of drug metabolism by chloramphenicol. Lancet 1969 Dec 27; II: 1397–9

    Google Scholar 

  156. Yacobi A, Lai C-M, Levy G. Pharmacokinetic and pharmacodynamic studies of acute interaction between warfarin enantiomers and chloramphenicol in rats. J Pharmacol Exp Ther 1984; 231(1): 80–4

    PubMed  CAS  Google Scholar 

  157. Hassall C, Feetam CL, Leach RH, et al. Potentiation of warfarin by co-trimoxazole [letter]. Lancet 1975 Dec 6; II: 1155–56

    Google Scholar 

  158. O’Reilly RA. Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med 1980 Jan 3; 302(1): 33–5

    PubMed  Google Scholar 

  159. Lodwick R, McConkey B, Brown AM. Life threatening interaction between tamoxifen and warfarin. BMJ 1987 Oct 31; 295: 1141

    PubMed  CAS  Google Scholar 

  160. Tenni P, Lalich DL, Byrne MJ. Life threatening interaction between tamoxifen and warfarin. BMJ 1989 Jan 14; 298: 93

    PubMed  CAS  Google Scholar 

  161. Singleton JD, Conyers L. Warfarin and azathioprine: an important drug interaction. Am J Med 1992 Feb; 92: 217

    PubMed  CAS  Google Scholar 

  162. Rivier G, Khamashta MA, Hughes GRV. Warfarin and azathioprine: a drug interaction does exist [letter]. Am J Med 1993 Sep; 95: 342

    PubMed  CAS  Google Scholar 

  163. Scarfe MA, Israel MK. Possible drug interaction between warfarin and combination of levamisole and fluorouracil. Ann Pharmacother 1994 Apr; 28(4): 464–7

    PubMed  CAS  Google Scholar 

  164. Chlebowski RT, Gota CH, Chan KK, et al. Clinical and pharmacokinetic effects of combined warfarin and 5-fluorouracil in advanced colon cancer. Cancer Res 1982; 42: 4827–30

    PubMed  CAS  Google Scholar 

  165. Bruning PF, Bonfrèr JGM. Aminoglutethimide and oral anticoagulant therapy [letter]. Lancet 1983 Sep 3; II: 582

    Google Scholar 

  166. Lonning PE, Kvinnsland S, Jahren G. Aminoglutethimide and warfarin. A new important drug interaction. Cancer Chemother Pharmacol 1984; 12: 10–12

    PubMed  CAS  Google Scholar 

  167. Hall G, Lind MJ, Huang M, et al. Intravenous infusions of ifosfamide/mesna and pertubation of warfarin anticoagulant control. Postgrad Med J 1990; 66: 860–1

    PubMed  CAS  Google Scholar 

  168. O’Reilly RA, Trager WF, Motley CH, et al. Interaction of secobarbital with warfarin pseudoracemates. Clin Pharmacol Ther 1980 (Aug); 28(2): 187–95

    PubMed  Google Scholar 

  169. MacDonald MG, Robinson DS, Sylwester D, et al. The effects of phenobarbital, chloral betaine, and glutethimide administration on warfarin plasma levels and hypopro-thrombinemic responses in man. Clin Pharmacol Ther 1969; 10(1): 80–4

    PubMed  CAS  Google Scholar 

  170. Udall JA. Clinical implications of warfarin interactions with five sedatives. Am J Cardiol 1975 Jan; 35: 67–71

    PubMed  CAS  Google Scholar 

  171. Antlitz AM, Tolentino M, Kosai MF. Effect of butabarbital on orally administered anticoagulants. Curr Ther Res 1968 Feb; 10(2): 70–3

    PubMed  CAS  Google Scholar 

  172. Kopera H, Schenk H, Stulemeijer S. Phenprocoumon requirement, whole blood coagulation time, bleeding time and plasma g-GT in patients receiving mianserin. Eur J Clin Pharmacol 1978; 13: 351–6

    PubMed  CAS  Google Scholar 

  173. Pond SM, Graham GG, Birkett DJ, et al. Effects of tricyclic antidepressants on drug metabolism. Clin Pharmacol Ther 1975; 18(2): 191–9

    PubMed  CAS  Google Scholar 

  174. Vesell ES, Passananti GT, Greene FE. Impairment of drug metabolism in man by allopurinol and nortriptyline. N Engl J Med 1970 Dec 31; 283(27): 1484–8

    PubMed  CAS  Google Scholar 

  175. Ross JRY, Beeley L. Interaction between carbamazepine and warfarin. BMJ 1980 Jun 14; 280: 1415–6

    PubMed  CAS  Google Scholar 

  176. Denbow CE, Fraser HS. Clinically significant hemorrhage due to warfarin-carbamazepine interaction. South Med J 1990 Aug; 83(8): 981

    PubMed  CAS  Google Scholar 

  177. Hansen JM, Siersbaek-Nielsen K, Skovsted L. Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin Pharmacol Ther 1971; 12(3): 539–43

    PubMed  CAS  Google Scholar 

  178. Krämer G, Tettenborn B, Klosterskov-Jensen P, et al. Oxcarbazepine does not affect the anticoagulant activity of warfarin. Epilepsia 1992 Nov; 33(6): 1145–8

    PubMed  Google Scholar 

  179. Nappi JM. Warfarin and phenytoin interaction [letter]. Ann Intern Med 1979 May; 90(5): 852

    PubMed  CAS  Google Scholar 

  180. Levine M, Sheppard I. Biphasic interaction of phenytoin with warfarin. Clin Pharm 1984 Mar/Apr; 3: 200–3

    PubMed  CAS  Google Scholar 

  181. Panegyres PK, Rischbieth RH. Fatal phenytoin warfarin interaction [letter]. Postgrad Med J 1991; 67: 98

    PubMed  CAS  Google Scholar 

  182. O’Reilly RA. Dynamic interaction between disulfiram and separated enantiomorphs of racemic warfarin. Clin Pharmacol Ther 1981 Mar; 29(3): 332–6

    PubMed  Google Scholar 

  183. Mönig H, Baese C, Heidemann HT, et al. Effect of oral contraceptive steroids on the pharmacokinetics of phenprocoumon. Br J Clin Pharmacol 1990; 30: 115–18

    PubMed  Google Scholar 

  184. De Teresa E, Vera A, Ortigosa J, et al. Interaction between anticoagulants and contraceptives: an unsuspected finding. BMJ 1979 Nov 17; 2: 1260–1

    PubMed  Google Scholar 

  185. Meeks ML, Mahaffey KW, Katz MD. Danazol increases the anticoagulant effect of warfarin. Ann Pharmacother 1992 May; 26: 641–2

    PubMed  CAS  Google Scholar 

  186. Husted S, Andreasen F, Foged L. Increased sensivity to phenprocoumon during methyltestosterone therapy. Eur J Clin Pharmacol 1976; 10: 209–16

    Google Scholar 

  187. Schrogie JJ, Solomon HM. The anticoagulant response to bis-hydroxycoumarin. II. The effect of D-thyroxine, clofibrate, and norethandrolone. Clin Pharmacol Ther 1967; 8 (1 Pt 1): 70–7

    PubMed  CAS  Google Scholar 

  188. Costigan DC, Freedman MH, Ehrlich RM. Potentiation of oral anticoagulant effect by L-thyroxine. Clin Pediatr 1984 Mar; 23(3): 172–4

    CAS  Google Scholar 

  189. Rice AJ, McIntosh TJ, Fouts JR, et al. Decreased sensitivity to warfarin in patients with myxedema. Am J Med Sci 1971 Oct; 262(4): 211–15

    PubMed  CAS  Google Scholar 

  190. Self TH, Evans WE, Ferguson T. Drug enhancement of warfarin activity [letter]. Lancet 1975 Sep 20; II: 557–8

    Google Scholar 

  191. Jähnchen E, Meinertz T, Gilfrich HJ. Interaction of allopurinol with phenprocoumon in man. Klin Wochenschr 1977; 55: 759–61

    PubMed  Google Scholar 

  192. Pan HYM, Ng RP The effect of nootropil in a patient on warfarin [letter]. Eur J Clin Pharmacol 1983; 24: 711

    PubMed  CAS  Google Scholar 

  193. Ingerslev J, Mouritzen C, Stenbjerg S. Pentoxifylline does not interfere with stable coumarin anticoagulant therapy: a clinical study. Pharmatherapeutica 1986; 4(9): 595–600

    PubMed  CAS  Google Scholar 

  194. Skovsted L, Kristensen M, Hansen JM, et al. The effect of different oral anticoagulants on diphenylhydantoin (DPH) and tolbutamide metabolism. Acta Med Scand 1976; 199: 513–5

    PubMed  CAS  Google Scholar 

  195. Kristensen M, Hansen JM. Accumulation of chlorpropamide caused by dicoumarol. Acta Med Scand 1968; 183: 83–6

    PubMed  CAS  Google Scholar 

  196. Forfar JC. A 7-year analysis of haemorrhage in patients on long-term anticoagulant treatment. Br Heart J 1979; 42: 128–32

    PubMed  CAS  Google Scholar 

  197. Williams JRB, Griffin JP, Parkins A. Effect of concomitantly administered drugs on the control of long term anticoagulant therapy. Q J Med 1976 (XLV): 63–73

  198. Lo ACT, Chan K, Yeung JHK, et al. The effects of Danshen (Salvia miltiorrhiza) on pharmacokinetics and pharmacodynamics of warfarin in rats. Eur J Drug Metab Pharmacokinet 1992; 17(4): 257–62

    PubMed  CAS  Google Scholar 

  199. Rosenthal G. Interaction of ascorbic acid and warfarin [letter]. JAMA 1971 Mar 8; 215(10): 1671

    PubMed  CAS  Google Scholar 

  200. Spigset O. Reduced effect of warfarin caused by ubidecarenone [letter]. Lancet 1994 Nov 12; 344: 1372–3

    PubMed  CAS  Google Scholar 

  201. Steinijans VW, Hartmann M, Huber R et al. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 1992; 30 Suppl. 1: S63–S67

    PubMed  Google Scholar 

  202. Physcians Desk Reference. Montvale: Medical Economics Production Co., 1995

  203. Estes JW. Clinical pharmacokinetics of heparin. Clin Pharmacokinet 1980; 5: 204–20

    PubMed  CAS  Google Scholar 

  204. Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1992; 22(5): 359–74

    PubMed  CAS  Google Scholar 

  205. Hirsh J. Heparin. N Engl J Med 1991 May 30; 324(22): 1565–74

    PubMed  CAS  Google Scholar 

  206. Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991 Feb; 151: 333–7

    PubMed  CAS  Google Scholar 

  207. Col J, Col-Debeys C, Lavenne-Pardonge E, et al. Propylene glycol-induced heparin resistance during nitroglycerin infusion. Am Heart J 1985; 110 (1 Pt 1): 171–3

    PubMed  CAS  Google Scholar 

  208. Habbab MA, Haft JI. Intravenous nitroglycerin and heparin resistance [letter]. Ann Intern Med 1986; 105: 305

    PubMed  CAS  Google Scholar 

  209. Habbab MA, Haft JI. Heparin resistance induced by intravenous nitroglycerin. A word of caution when both drugs are used concomitantly. Arch Intern Med 1987 May; 147: 857–60

    PubMed  CAS  Google Scholar 

  210. Bode V, Welzel D, Franz G, et al. Absence of drug interaction between heparin and nitroglycerin. Randomized placebo-controlled crossover study. Arch Intern Med 1990 Oct; 150: 2117–9

    PubMed  CAS  Google Scholar 

  211. Lepor NE, Amin DK, Berberian L, et al. Does nitroglycerin induce heparin resistance? Clin Cardiol 1989 Aug; 12: 432–4

    PubMed  CAS  Google Scholar 

  212. Berk SI, Grunwald A, Pal S, et al. Effect of intravenous nitroglycerin on heparin dosage requirements in coronary artery disease. Am J Cardiol 1993 Aug 15; 72: 393–6

    PubMed  CAS  Google Scholar 

  213. Becker RC, Corrao JM, Bovill EG, et al. Intravenous nitroglycerin-induced heparin resistance: a qualitative antithrombin III abnormality. Am Heart J 1990 Jun; 119(6): 1254–61

    PubMed  CAS  Google Scholar 

  214. Walker AM, Jick H. Predictors of bleeding during heparin therapy. JAMA 1980 Sep 12; 244(11): 1209–12

    PubMed  CAS  Google Scholar 

  215. Heiden D, Rodvien R, Mielke CH. Heparin bleeding, platelet dysfunction, and aspirin [letter]. JAMA 1981 Jul 24/31; 246(4): 330–1

    PubMed  CAS  Google Scholar 

  216. Zahger D, Maaravi Y, Matzner Y, et al. Partial resistance to anticoagulation after streptokinase treatment for acute myocardial infarct. Am J Cardiol 1990 Jul 1; 66: 28–30

    PubMed  CAS  Google Scholar 

  217. Mungall D, Floyd R. Bayesian forecasting of APTT response to continuously infused heparin with and without warfarin administration. J Clin Pharmacol 1989; 29: 1043–7

    PubMed  CAS  Google Scholar 

  218. Desmond PV, Roberts RK, Wood AJJ, et al. Effect of heparin administration on plasma binding of benzodiazepines. Br J Clin Pharmacol 1980; 9: 171–5

    PubMed  CAS  Google Scholar 

  219. Storstein L, Janssen H. Studies on digitalis. VI. The effect of heparin on serum protein binding of digitoxin and digoxin. Clin Pharmacol Ther 1976; 20: 15–23

    PubMed  CAS  Google Scholar 

  220. Lohman JJHM, Hooymans PM, Koten MLP, et al. Effect of heparin on digitoxin protein binding. Clin Pharmacol Ther 1985; 37: 55–60

    PubMed  CAS  Google Scholar 

  221. De Smet AAEA, Joen MCN, van Oeveren W, et al. Increased anticoagulation during cardiopulmonary bypass by aprotinin. J Thorac Cardiovasc Surg 1990; 100: 520–7

    PubMed  Google Scholar 

  222. Levy JH, Salmenpera MT. Increased anticoagulation during cardiopulmonary bypass by aprotinin [letter]. J Thorac Cardiovasc Surg 1991; 102: 802

    PubMed  CAS  Google Scholar 

  223. Durand D, Ader J-L, Rey J-P, et al. Inducing hyperkalemia by converting enzyme inhibitors and heparin. Kidney Int 1988; 34 Suppl 25: S196–7

    Google Scholar 

  224. Thürmann P, Harder S, Kirchmaier CM. Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393). Eur J Clin Pharmacol 1995; 48: 241–7

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, University Hospital Frankfurt/Main, Theodor Stern Kai 7, D-60590, Frankfurt am Main, Germany

    Sebastian Harder & Petra Thürmann

Authors
  1. Sebastian Harder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Petra Thürmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harder, S., Thürmann, P. Clinically Important Drug Interactions with Anticoagulants. Clin-Pharmacokinet 30, 416–444 (1996). https://doi.org/10.2165/00003088-199630060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199630060-00002

Keywords

Search

Navigation